MCK vs AMRX vs COR Stock Comparison

Mckesson, Amneal Pharmaceuticals and Cencora Prices as of Nov 13, 2026 Peers: Industry group
MCK Mckesson Corp
$1,102.82 +12.7% 1M +30.3% 1Y
Market cap
$129.52B
P/E
27.6x
Revenue (TTM)
$418.79B
Div. yield
0.00%
Drug Distribution Healthcare
5 wins
COR Cencora, Inc.
$359.02 +6.8% 1M -1.8% 1Y
Market cap
$69.49B
P/E
22.6x
Revenue (TTM)
$337.40B
Div. yield
–
Drug Distribution Healthcare
2 wins

Head to Head

11 decided of 12

Mckesson leads on 5 of the 12 questions below (Mckesson 5, Amneal Pharmaceuticals 4, Cencora 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionMCKAMRXCORLeader
Larger companyMarket capitalisation $129.52B $7.19B $69.49B MCK
Cheaper on earningsLower P/E, profitable companies only 27.6x 53.9x 22.6x COR
Cheaper on forward earningsLower price / next fiscal year consensus EPS 22.8x 21.4x 18.8x COR
Faster revenue growthRevenue growth, trailing twelve months +8.2% +8.9% +5.0% AMRX
More profitableNet margin, trailing twelve months 1.1% 4.2% — AMRX
Better return on capitalReturn on invested capital 98.7% 14.3% — MCK
Less leveragedLower net debt / EBITDA 0.4x 4.3x — MCK
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +30.3% +85.6% -1.8% AMRX
Better 5-year returnAnnualised price return, 5 years +37.5%/yr +32.7%/yr +23.4%/yr MCK
Less volatileAnnualised volatility, 1 year 31.4% 34.3% 33.4% MCK
Higher overall scoreMean of the five percentile scores vs peers 58/100 69/100 56/100 AMRX

Percentile Scorecard

MCKAMRXCOR

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisMCKAMRXCOR
Valuation 65 #10 of 27 90 #69 of 660 54 #13 of 27
Growth 56 #12 of 26 70 #189 of 619 64 #10 of 26
Profitability 56 #12 of 26 87 #80 of 595 64 #10 of 26
Financial Health 56 #12 of 26 11 #606 of 683 –
Shareholder Returns 59 #8 of 18 89 #53 of 459 41 #11 of 18
Overall 58 69 56
  • MCK ranked among 27 companies in Healthcare Payers and Distributors
  • AMRX ranked among 695 companies in Pharmaceuticals and Biotechnology
  • COR ranked among 27 companies in Healthcare Payers and Distributors

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodMCKAMRXCORSPY
1 month +12.7%+13.1%+6.8% -2.0%
3 months +26.9%+17.8%+14.4% -2.8%
6 months +45.0%+79.2%+39.3% +2.0%
Year to date +34.4%+69.7%+6.3% +10.6%
1 year +30.3%+85.6%-1.8% +12.2%
3 years +143.0%+367.8%+84.7% +68.1%
3 years, per year +34.5%+67.3%+22.7% +18.9%
5 years +390.5%+310.4%+186.4% +61.4%
5 years, per year +37.5%+32.7%+23.4% +10.1%
10 years +671.0%—+354.9% +248.5%
10 years, per year +22.7%—+16.4% +13.3%

Risk

MeasureMCKAMRXCORSPY
Volatility, 1Y 31.4%34.3%33.4% 13.6%
Downside volatility, 1Y 27.2%30.7%40.0% 13.9%
Beta vs S&P 500, 1Y -0.180.670.05 1.00
Return / volatility, 1Y 0.972.49-0.05 0.90
Max drawdown, 5Y -27.2%-75.4%-32.6% -25.4%
From 52-week high 0.0%-1.5%-4.2% -3.2%
52-week high $1,102.82$21.71$374.75 $779.14
52-week low $725.17$11.52$252.74 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleMCKAMRXCOR
P/E now vs peer median 27.3xmedian 25.2x 53.8xmedian 17.0x 22.6xmedian 25.2x
P/S now vs peer median 0.3xmedian 0.4x 2.3xmedian 8.4x 0.2xmedian 0.4x
EV/EBITDA now vs peer median 17.4xmedian 14.5x 15.1xmedian 14.6x —median 14.5x
P/FCF now vs peer median 17.9xmedian 16.5x 193.9xmedian 19.0x 14.5xmedian 16.5x
P/B now vs peer median -32.2xmedian 2.7x 14.0xmedian 2.0x 18.6xmedian 2.7x
PEG now vs peer median 1.72median 1.72 0.65median 0.43 —median 1.72

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsMCKAMRXCOR
Revenue $418.79B $3.20B $337.40B
Gross profit $15.37B $1.29B $13.87B
Operating income $6.69B $478.99M $3.93B
Net income $5.43B $175.49M $3.51B
Free cash flow $7.11B $38.42M –
R&D – $180.59M –
EPS (diluted) $40.27 $0.40 –
Cash & equivalents $6.53B $157.40M $4.88B
Total debt $9.21B $3.12B –
Shares (diluted) 116.70M 335.73M 193.94M
Enterprise value $110.89B $6.43B $69.49B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricMCKAMRXCOR
P/E 27.3x 53.8x 22.6x
P/FCF 17.9x 193.9x 14.5x
P/Operating cash flow 17.0x 41.2x 14.3x
P/S 0.3x 2.3x 0.2x
P/B -32.2x 14.0x 18.6x
P/Tangible book -16.1x -7.3x 18.6x
EV/EBITDA 17.4x 15.1x –
EV/EBIT 19.4x 21.7x –
EV/Revenue 0.3x 3.3x 0.2x
EV/FCF 18.3x 271.0x –
EV/Operating cash flow 17.3x 57.6x 14.3x
PEG (3Y EPS CAGR) 1.72 0.65 –

Growth

14 metrics
MetricMCKAMRXCOR
Revenue growth (1Y) 8.2% 8.9% 5.0%
Revenue CAGR (3Y) 12.9% 10.2% 8.8%
Gross profit growth (1Y) 11.8% 19.2% 20.8%
Gross profit CAGR (3Y) 7.6% 15.0% 15.7%
Operating income growth (1Y) 27.3% 33.8% 49.5%
Operating income CAGR (3Y) 16.1% 28.4% 18.9%
Net income growth (1Y) 28.5% 271.2% 124.0%
Net income CAGR (3Y) 14.2% 53.6% 26.3%
EPS growth (1Y) 24.2% 2,085% –
EPS CAGR (3Y) 15.9% 83.1% –
Operating cash flow growth (1Y) 9.3% -44.9% 23.6%
Operating cash flow CAGR (3Y) 15.2% -1.1% 7.0%
Free cash flow growth (1Y) 11.8% -84.6% –
Free cash flow CAGR (3Y) 16.3% -35.0% –

Profitability

14 metrics
MetricMCKAMRXCOR
Gross margin 3.7% 40.2% –
EBITDA margin 1.8% 21.5% –
Operating margin 1.6% 15.0% –
Pretax margin 1.6% 6.9% –
Net margin 1.1% 4.2% –
FCF margin 1.7% 1.2% –
Operating cash flow margin 1.8% 5.7% 1.4%
Return on equity – 74.3% 101.2%
Return on assets 6.0% 4.6% 4.1%
Return on invested capital 98.7% 14.3% –
Return on capital employed 42.0% 14.1% –
Asset turnover 4.6x 0.7x 3.9x
Cash conversion (OCF / net income) 1.4x 1.0x 1.4x
Stock comp / revenue – 1.2% –

Financial Health

11 metrics
MetricMCKAMRXCOR
Debt / assets 10.0% 59.2% –
Debt / equity -2.3x 5.9x –
Net debt / EBITDA 0.4x 4.3x –
Debt / FCF 1.3x 81.2x –
Liabilities / assets 104.3% 89.9% –
Equity / assets -4.3% 10.1% 4.2%
Interest coverage 21.9x – –
Current ratio 0.9x 1.9x 0.9x
Quick ratio 0.5x 1.1x –
Cash ratio 0.1x 0.1x –
Altman Z-score 5.83 1.96 –

Shareholder Returns

7 metrics
MetricMCKAMRXCOR
Dividend yield 0.3% – 0.9%
Net buyback yield 5.2% 0.0% –
Shareholder yield 5.6% 0.0% 0.9%
Payout ratio (earnings) 7.4% – –
Payout ratio (FCF) 5.6% – –
Dividend growth (1Y) 10.5% – –
Dividend CAGR (3Y) 9.8% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusMCKAMRXCOR
Forward P/E 22.8xFY2026 21.4xFY2026 18.8xFY2027
EPS, next fiscal year $48.34FY2026 $1.00FY2026 $19.07FY2027
EPS growth, next FY +23.6%FY2026 +20.5%FY2026 +6.1%FY2027
EPS growth, the year after +11.9% +26.0% +17.4%
Revenue, next fiscal year $447.65BFY2026 $3.30BFY2026 $328.27BFY2027
Revenue growth, next FY +11.0%FY2026 +9.1%FY2026 -2.7%FY2027
Revenue growth, the year after +1.5% +12.6% +19.1%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersMCKAMRXCOR
Held by institutions 89.1% 51.0% 94.7%
Institutions holding 2,014 310 1,345
Change in shares held, QoQ -0.7% +1.3% +15.7%
Institutions buying 883 182 542
Institutions selling 793 86 612
Buyers to sellers 1.11 2.12 0.89

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

MCKAMRXCOR
MCK 1.00 0.13 0.71
AMRX 0.13 1.00 0.06
COR 0.71 0.06 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, MCK, AMRX and COR?

Mckesson (MCK) is the largest by market capitalisation: Mckesson (MCK) $129.52B, Amneal Pharmaceuticals (AMRX) $7.19B, Cencora (COR) $69.49B.

Which stock is cheaper, MCK, AMRX and COR?

Cencora (COR) trades on the lowest price-to-earnings ratio (Mckesson (MCK) 27.6x, Amneal Pharmaceuticals (AMRX) 53.9x, Cencora (COR) 22.6x). On next year's consensus earnings, Cencora (COR) is cheapest (Mckesson (MCK) 22.8x, Amneal Pharmaceuticals (AMRX) 21.4x, Cencora (COR) 18.8x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Amneal Pharmaceuticals (AMRX) grew revenue fastest over the trailing twelve months: Mckesson (MCK) +8.2%, Amneal Pharmaceuticals (AMRX) +8.9%, Cencora (COR) +5.0%.

Which company is more profitable?

Amneal Pharmaceuticals (AMRX) has the highest net margin (Mckesson (MCK) 1.1%, Amneal Pharmaceuticals (AMRX) 4.2%). On return on invested capital, Mckesson (MCK) leads (Mckesson (MCK) 98.7%, Amneal Pharmaceuticals (AMRX) 14.3%).

Which stock has performed better?

Over the past year Amneal Pharmaceuticals (AMRX) returned the most: Mckesson (MCK) +30.3%, Amneal Pharmaceuticals (AMRX) +85.6%, Cencora (COR) -1.8%. Over five years, Mckesson (MCK) compounded fastest (Mckesson (MCK) +37.5%/yr, Amneal Pharmaceuticals (AMRX) +32.7%/yr, Cencora (COR) +23.4%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Mckesson (MCK) 0.00%, Amneal Pharmaceuticals (AMRX) 0.00%, Cencora (COR) 0.00%. Amneal Pharmaceuticals (AMRX) and Cencora (COR) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Mckesson (MCK) has been the steadiest (Mckesson (MCK) 31.4%, Amneal Pharmaceuticals (AMRX) 34.3%, Cencora (COR) 33.4%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, MCK, AMRX and COR?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Mckesson (MCK) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.